Perspective
Volume 16:05, 2025

Journal of AIDS & Clinical Research

ISSN: 2155-6113

Open Access

Zidovudine: Balancing Efficacy, Safety, and Dosing

Grace Mwai*

Department of HIV and Public Health, University of Nairobi, Nairobi 00100, Kenya

Introduction

The landscape of HIV treatment has profoundly changed, with antiretroviral therapies offering life-saving interventions and significantly reducing transmission rates. Zidovudine, a foundational antiretroviral drug, has been central to these advancements, particularly in preventing mother-to-child transmission (PMTCT) and managing HIV infection. Ongoing research continually refines our understanding of its effectiveness, safety profiles, and optimal use in diverse populations and clinical contexts.

Here's the thing: a study explored the pharmacokinetics and pharmacodynamics of zidovudine, lamivudine, and lopinavir/ritonavir in pregnant women with HIV and their infants in Uganda. This work provided crucial data on drug exposure during pregnancy, which is vital for optimizing dosing strategies to prevent mother-to-child transmission and ensure maternal and infant safety. Understanding these drug levels helps fine-tune treatment, minimizing side effects while maintaining efficacy, especially for vulnerable populations like pregnant women and newborns [1].

Another Ethiopian study assessed the safety and efficacy of various antiretroviral prophylaxis regimens, including those involving zidovudine, in HIV-exposed infants. It's important because it contributes to our understanding of how well these treatments work in real-world settings to prevent HIV acquisition in infants while minimizing adverse effects. The data helps inform national guidelines for infant prophylaxis in resource-limited countries [2].

This review delves into the neurotoxicity associated with HIV treatment, including older drugs like zidovudine, and explores neuroprotective strategies. What this really means is that while antiretrovirals are life-saving, some can have neurological side effects. This paper synthesizes current knowledge on how these drugs impact the central nervous system and highlights ways to mitigate damage, ensuring a more holistic approach to patient care by balancing viral suppression with neurological health [3].

Let's break it down: this case report describes the unique pharmacokinetic profile of zidovudine in a preterm neonate exposed to HIV. Preterm infants often metabolize drugs differently than full-term babies, making precise dosing challenging. This specific data helps clinicians understand how zidovudine is absorbed, distributed, metabolized, and excreted in this very vulnerable population, enabling safer and more effective prophylaxis to prevent HIV transmission [4].

This retrospective cohort study from Ethiopia looked at the long-term efficacy and safety of antiretroviral therapy, including zidovudine, for preventing mother-to-child transmission of HIV. What this means is that in resource-limited settings, consistent and effective PMTCT programs are absolutely essential. The study provides evidence on the real-world impact of these interventions over time, highlighting both successes and areas for improvement in national health strategies [5].

This research explored how combined antiretroviral therapy and zidovudine monotherapy affect mitochondrial function and disease in people with HIV. It's a critical area of study because mitochondrial toxicity is a known side effect of some older Antiretrovirals like zidovudine, contributing to conditions like lipodystrophy and myopathy. Understanding these impacts helps clinicians manage long-term complications and potentially guides future drug development towards less toxic regimens [6].

Here's the thing about zidovudine: while revolutionary for HIV treatment, it can induce myopathy and mitochondrial dysfunction. This paper thoroughly reviews this specific adverse effect. What this really means for patients and clinicians is the importance of monitoring for muscle weakness and related symptoms in individuals on zidovudine and considering alternative therapies or management strategies to preserve muscle health and overall quality of life [7].

This Ugandan cohort study investigated maternal and infant zidovudine concentrations and how they correlate with HIV-1 mother-to-child transmission rates. It's a critical piece of the puzzle because adequate drug levels in both mother and infant are paramount for effective prevention. The findings help determine optimal dosing and adherence strategies to minimize transmission risk, especially in high-burden settings where PMTCT programs are crucial [8].

Let's break it down: this study from Cameroon focused on the safety and efficacy of various antiretroviral regimens, including those featuring zidovudine, for preventing mother-to-child transmission of HIV. The data is important because it provides localized evidence on the performance of these interventions in a specific African context. It informs public health decisions, ensuring that the most effective and safe prophylaxis options are implemented to protect infants from HIV [9].

This systematic review and meta-analysis synthesizes evidence on the effect of antiretroviral prophylaxis, including zidovudine, for preventing mother-to-child transmission of HIV in Ethiopia. What this really means is that by pooling data from multiple studies, it provides a robust overview of the effectiveness of these interventions. It's a powerful tool for policymakers and clinicians, offering high-level evidence to guide national PMTCT strategies and improve health outcomes for mothers and infants [10].

Description

Understanding drug exposure is fundamental for effective HIV treatment, particularly when it comes to vulnerable populations. A study from Uganda precisely investigated the pharmacokinetics and pharmacodynamics of zidovudine, lamivu-

dine, and lopinavir/ritonavir in pregnant women with HIV and their infants [1]. This research delivered crucial data, helping to optimize dosing strategies that prevent mother-to-child transmission while also ensuring maternal and infant safety. What this really means is that knowing drug levels allows for fine-tuning treatment, aiming to minimize side effects while maintaining efficacy for both mother and newborn. Similarly, a unique case report detailed the pharmacokinetic profile of zidovudine in a preterm neonate exposed to HIV [4]. Preterm infants metabolize drugs differently, which makes precise dosing particularly challenging. This specific data is vital for clinicians to understand how zidovudine is absorbed, distributed, metabolized, and excreted in this extremely vulnerable group, leading to safer and more effective prophylaxis against HIV transmission. Another Ugandan cohort study reinforced this by investigating maternal and infant zidovudine concentrations and their correlation with HIV-1 mother-to-child transmission rates [8]. Adequate drug levels in both mother and infant are paramount, and these findings help determine optimal dosing and adherence strategies, especially in high-burden settings where PMTCT programs are essential.

The safety and efficacy of antiretroviral prophylaxis regimens in preventing mother-to-child transmission of HIV are critical, particularly in resource-limited countries. An Ethiopian study assessed various regimens, including those with zidovudine, in HIV-exposed infants [2]. This contributes significantly to understanding how well these treatments perform in real-world settings, working to prevent HIV acquisition in infants while minimizing adverse effects. This data directly informs national guidelines for infant prophylaxis. A retrospective cohort study also from Ethiopia further examined the long-term efficacy and safety of antiretroviral therapy, including zidovudine, for PMTCT [5]. It highlights that consistent and effective PMTCT programs are absolutely essential in these settings, providing real-world evidence on the long-term impact of these interventions and pinpointing areas for improvement in national health strategies. In Cameroon, another study focused on the safety and efficacy of antiretroviral regimens, again featuring zidovudine, for preventing mother-to-child transmission of HIV [9]. This offers localized evidence on the performance of these interventions within a specific African context, guiding public health decisions towards the most effective and safe prophylaxis for infants.

To provide a comprehensive overview, a systematic review and meta-analysis synthesized evidence on the effect of antiretroviral prophylaxis, including zidovudine, for preventing mother-to-child transmission of HIV in Ethiopia [10]. What this really means is that by pooling data from multiple studies, a robust and high-level overview of intervention effectiveness becomes available. This is a powerful tool for policymakers and clinicians, as it guides national PMTCT strategies and aims to improve health outcomes for mothers and infants. The combined evidence underscores zidovudine's foundational role in these prevention efforts, offering a clearer picture of its overall impact across various studies.

Beyond its efficacy, understanding the adverse effects of zidovudine is crucial for holistic patient care. A review delved into the neurotoxicity associated with HIV treatment, specifically including older drugs like zidovudine, and explored neuroprotective strategies [3]. While antiretrovirals save lives, some, like zidovudine, can have neurological side effects. This paper synthesizes current knowledge on how these drugs affect the central nervous system and suggests ways to lessen damage, balancing viral suppression with neurological health. Additionally, research explored how combined antiretroviral therapy and zidovudine monotherapy impact mitochondrial function and disease in people with HIV [6]. Mitochondrial toxicity is a known side effect of some older Antiretrovirals, including zidovudine, contributing to conditions like lipodystrophy and myopathy. Understanding these impacts helps clinicians manage long-term complications and might even guide future drug development toward less toxic regimens. Here's the thing about zidovudine: it can induce myopathy and mitochondrial dysfunction, as thoroughly reviewed in another paper [7]. What this really means for patients and clinicians is the importance of monitoring for muscle weakness and related symptoms in individuals on zidovudine, potentially considering alternative therapies or management strategies to preserve muscle health and overall quality of life.

Conclusion

This collection of studies offers a broad look at zidovudine, a key antiretroviral, particularly concerning its use in HIV treatment and the prevention of mother-to-child transmission. Research from Uganda explores the pharmacokinetics of zidovudine and other antiretrovirals in pregnant women and their infants, providing essential data for optimizing dosing and ensuring both maternal and infant safety. This type of work helps fine-tune treatments, balancing efficacy with minimal side effects in vulnerable groups like newborns and pregnant women. Studies from Ethiopia and Cameroon further assess the safety and efficacy of zidovudine-containing antiretroviral prophylaxis regimens for HIV-exposed infants and in PMTCT programs within resource-limited settings. What this really means is consistent and effective prevention programs are vital, and these studies offer real-world evidence to inform national guidelines and public health decisions. One case report specifically details the unique pharmacokinetic profile of zidovudine in preterm neonates, addressing the challenges of precise dosing in this fragile population. Beyond its primary role, several papers delve into the potential adverse effects of zidovudine. Reviews and research examine its association with neurotoxicity and mitochondrial dysfunction, which can manifest as myopathy. Understanding these impacts is crucial for clinicians, helping them monitor for symptoms like muscle weakness and consider alternative therapies to safeguard long-term patient health. Here's the thing: while zidovudine has been revolutionary, these studies collectively underscore the ongoing need to balance its life-saving benefits with careful management of its potential side effects, especially as treatment strategies evolve. The work informs a holistic approach to patient care, ensuring viral suppression alongside neurological and muscular health.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Edward Ruzagira, Milcah Nakalema, Francis Mumbere, Noah Kiwanuka, Hellen Tumwebaze, Charles Mugisha. "Pharmacokinetics and pharmacodynamics of zidovudine, lamivudine, and lopinavir/ritonavir in pregnant women living with HIV and their infants: a prospective cohort study." *Antivir Ther* 29 (2024):10.3851/IMP4140.

2. Meklit Asfaw, Mekibib Legesse, Tezera Gebremariam, Seblewongel Tegegne, Fikiru Abera, Adhanom Gebresilase. "Safety and Efficacy of Antiretroviral Prophylaxis in HIV-Exposed Infants in Ethiopia." *HIV AIDS* (Auckl) 15 (2023):111-120.

3. Anna Rzepiela, Sebastian Lisiak, Justyna Słońska, Anna Badyra, Jakub Radzik, Beata Szalewska-Pałasz. "Neurotoxicity and Neuroprotection in the Treatment of HIV Infection." *Int J Mol Sci* 23 (2022):7660.

4. Erin de Leon, Jonathan Wajchendler, Patrick O'Hara, Mary K Cwik, Kimberly A Johnson, Stephanie D Davis. "Pharmacokinetic Profile of Zidovudine in a Preterm Neonate with HIV Exposure: A Case Report." *J Pediatr Pharmacol Ther* 26 (2021):228-232.

5. Seblewongel Tegegne, Meseret M Mengesha, Meseret A Belete, Fikiru Abera, Solomon Shiferaw. "Long-term *Efficacy and Safety of Antiretroviral Therapy* (ART) for Preventing Mother-to-Child Transmission (PMTCT) of HIV in a Resource-Limited Setting in Ethiopia: A Retrospective Cohort Study." HIV AIDS (Auckl) 13 (2021):219-228.

6. Romain Guedj, Hayat Moussali, Virginie Le Moing, Claire Flandrois, Nathalie De Luca, Olivier Boyer. "The impact of combined antiretroviral therapy and zidovudine monotherapy on mitochondrial function and disease in HIV-infected patients." *J Antimicrob Chemother* 75 (2020):204-213.

7. Pablo Zegarra-Valdivia, Marcela Huayta, Marta Alcaraz-Verduguez, Juan Carlos Varela-Huerta, Sergio Valdivia-Velarde, Carlos A Morales. "Zidovudine-Induced Myopathy and Mitochondrial Dysfunction in HIV Infection." *J Neuromuscul Dis* 7 (2020):1-13.

8. Kibuuka Kintu, Todd D Ruel, Andrew Muganzi, Mary Nsereko, Christine Akankwatsa, Phillip J Rosenthal. "Maternal and infant zidovudine concentrations and impact on HIV-1 mother-to-child transmission rates in a Ugandan cohort." *AIDS Res Hum Retroviruses* 35 (2019):191-197.

9. Richard Nana, Brice Djeunang, Nathalie Zobo, Elvis Nsoga, Henri Koudou, Jeanne Ntsama. "Safety and efficacy of antiretroviral regimens for preventing mother-to-child transmission of HIV in Cameroon." *BMC Infect Dis* 19 (2019):44.

10. Abebe G Wondmie, Dawit B Demissie, Adamu T Dessie, Mengistie A Bekele. "Effect of Antiretroviral Prophylaxis for Prevention of Mother-to-Child Transmission of HIV in Ethiopia: A Systematic Review and Meta-Analysis." *AIDS Res Treat* 2019 (2019):4096053.

How to cite this article: Mwai, Grace. "Zidovudine: Balancing Efficacy, Safety, and Dosing." *J AIDS Clin Res* 16 (2025):1087.

Address for Correspondence: Grace, Mwai, Department of HIV and Public Health, University of Nairobi, *Nairobi* 00100, Kenya, E-mail: grace.mwai@uon.ac.ke

Received: 01-Oct-2025, Manuscript No. jar-25-177618; **Editor assigned:** 03-Oct-2025, PreQC No. P-177618; **Reviewed:** 17-Oct-2025, QC No. Q-177618; **Revised:** 22-Oct-2025, Manuscript No. R-177618; **Published:** 29-Oct-2025, DOI: 10.37421/2155-6113.2025.16.1087